| Literature DB >> 26590425 |
Man-Tzu Wang1, Matthew Holderfield1, Jacqueline Galeas1, Reyno Delrosario1, Minh D To1, Allan Balmain1, Frank McCormick2.
Abstract
K-Ras and H-Ras share identical effectors and have similar properties; however, the high degree of tumor-type specificity associated with K-Ras and H-Ras mutations suggests that they have unique roles in oncogenesis. Here, we report that oncogenic K-Ras, but not H-Ras, suppresses non-canonical Wnt/Ca(2+) signaling, an effect that contributes strongly to its tumorigenic properties. K-Ras does this by binding to calmodulin and so reducing CaMKii activity and expression of Fzd8. Restoring Fzd8 in K-Ras mutant pancreatic cells suppresses malignancy, whereas depletion of Fzd8 in H-Ras(V12)-transformed cells enhances their tumor initiating capacity. Interrupting K-Ras-calmodulin binding using genetic means or by treatment with an orally active protein kinase C (PKC)-activator, prostratin, represses tumorigenesis in K-Ras mutant pancreatic cancer cells. These findings provide an alternative way to selectively target this "undruggable" protein.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26590425 DOI: 10.1016/j.cell.2015.10.041
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582